These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27446325)

  • 1. Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy.
    Liu X; Guo H; Liu J; Shi B
    Exp Ther Med; 2016 Aug; 12(2):1093-1096. PubMed ID: 27446325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
    Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
    Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
    El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
    J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.
    Mitchell AL; Gan EH; Morris M; Johnson K; Neoh C; Dickinson AJ; Perros P; Pearce SH
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):437-42. PubMed ID: 23320840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.
    Vannucchi G; Campi I; Bonomi M; Covelli D; Dazzi D; Currò N; Simonetta S; Bonara P; Persani L; Guastella C; Wall J; Beck-Peccoz P; Salvi M
    Clin Exp Immunol; 2010 Sep; 161(3):436-43. PubMed ID: 20529087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis.
    Chen J; Chen G; Sun H
    Hormones (Athens); 2021 Jun; 20(2):279-286. PubMed ID: 33783712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
    Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An infant case of Graves' disease with ophthalmopathy.
    Kubo T; Shimizu J; Furujo M; Takeuchi A; Yoshioka-Iwaso H; Eguchi N; Fukuhara S; Koyama T; Kanadani T; Shiraga H; Oshima K
    Endocr J; 2005 Oct; 52(5):647-50. PubMed ID: 16284447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.
    Mukasa K; Yoshimura Noh J; Kouzaki A; Ohye H; Kunii Y; Watanabe N; Yoshihara A; Matsumoto M; Suzuki M; Ito K
    Endocr J; 2016; 63(2):151-7. PubMed ID: 26581710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab].
    Nielsen CH; El Fassi D; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2131-4. PubMed ID: 18565295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study.
    Deltour JB; d'Assigny Flamen M; Ladsous M; Giovansili L; Cariou B; Caron P; Drui D; Lebranchu P
    Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2013-2021. PubMed ID: 32405700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.